Patents by Inventor Eric M. Amendt

Eric M. Amendt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11639514
    Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: May 2, 2023
    Assignee: Leidos, Inc.
    Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
  • Publication number: 20200277643
    Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.
    Type: Application
    Filed: April 10, 2020
    Publication date: September 3, 2020
    Applicant: Leidos, Inc
    Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
  • Patent number: 10662457
    Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: May 26, 2020
    Assignee: Leidos, Inc.
    Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
  • Publication number: 20200155966
    Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.
    Type: Application
    Filed: February 16, 2018
    Publication date: May 21, 2020
    Applicant: Leidos, Inc.
    Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
  • Patent number: 9908064
    Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: March 6, 2018
    Assignee: Leidos, Inc.
    Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
  • Publication number: 20160230203
    Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.
    Type: Application
    Filed: January 29, 2016
    Publication date: August 11, 2016
    Applicant: Leidos, Inc.
    Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt